Current treatment and blueprint of CD30+ T-cell lymphomas: reports from the 19th European Hematology Association annual congress
10.3760/cma.j.issn.1009-9921.2014.09.003
- VernacularTitle:CD30+T细胞淋巴瘤的治疗现状及展望:第19届欧洲血液学会年会报道
- Author:
Feng CHEN
;
Depei WU
- Publication Type:Journal Article
- Keywords:
CD30+ T-cell lymphoma;
Treatment;
European Hematology Association annual congress
- From:
Journal of Leukemia & Lymphoma
2014;23(9):518-519,522
- CountryChina
- Language:Chinese
-
Abstract:
There is still no agreed standard of care for CD30+ T-cell lymphomas which are dominant in peripheral T-cell lymphoma.The combination of multidrug or dose-intensified chemotherapy regimen and consolidation of hematopoietic stem cell transplantation are widely used at present.In recent years,several clinical trails included certain new agents,such as etoposide,alemtuzumab,denileukin diftitox,bortezomib,romidepsin,lenalidomide,brentuximab vedotin,and so on,have demonstrated the promising outcome.Referring targeted therapies for relapsed/refractory CD30 + T-cell lymphomas,certain agents have been approved,such as pralatrexate,romidepsin,brentuximab vedotin (ALCL),belinostat,and the most encouraging agent is brentuximab vedotin.
